tert-Butyl 4-(3-bromo-5-(methoxycarbonyl)pyridin-2-yl)piperazine-1-carboxylate

Catalog No. :
ACTJFY812
CAS No. :
906559-32-8
Molecular Formula :
C16H22BrN3O4
Molecular Weight :
400.27

IUPAC Name:tert-butyl 4-(3-bromo-5-(methoxycarbonyl)pyridin-2-yl)piperazine-1-carboxylate

tert-Butyl 4-(3-bromo-5-(methoxycarbonyl)pyridin-2-yl)piperazine-1-carboxylate structure diagram
Pack SizePurityList PriceYour PriceGlobal StockUS StockQuantity
1g95%$1264.00Login to see priceInquiryInquiry

Products of AiFChem are all designed for scientific research only. Under no circumstances do we provide products or services for animal or personal utilization.

Product Information

Product Nametert-Butyl 4-(3-bromo-5-(methoxycarbonyl)pyridin-2-yl)piperazine-1-carboxylate
IUPAC Nametert-butyl 4-(3-bromo-5-(methoxycarbonyl)pyridin-2-yl)piperazine-1-carboxylate
Molecular FormulaC16H22BrN3O4
Molecular Weight400.27
SMILESO=C(N1CCN(C2=NC=C(C(OC)=O)C=C2Br)CC1)OC(C)(C)C
InChI KeyDSYBQUHXJQHJLU-UHFFFAOYSA-N
Synonym4-[3-Bromo-5-(methoxycarbonyl)pyridin-2-yl]piperazine, N1-BOC protected;tert-Butyl 4-[3-bromo-5-(methoxycarbonyl)pyridin-2-yl]piperazine-1-carboxylate;1-Piperazinecarboxylic acid, 4-[3-bromo-5-(methoxycarbonyl)-2-pyridinyl]-, 1,1-dimethylethyl ester;1,1-Dimethylethyl 4-[3-bromo-5-(methoxycarbonyl)-2-pyridinyl]-1-piperazinecar...
CAS No.906559-32-8

Synthetic Route by SureRoute

1. ACTJFY812 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7 In Stock
  2. Plus
  3. ACBWLE164 route compound structure diagram
    ACBWLE16478686-77-8 In Stock
  4. Then
  5. ACTJFY812 route product structure diagram
    ACTJFY812906559-32-8
Inquiry

2. ACTJFY812 Molecular Building Block Synthetic Route

Source: SureRouteAuthor: aifchem

  1. ACBRWP053 route compound structure diagram
    ACBRWP05357260-72-7 In Stock
  2. Plus
  3. reactant_2 route compound structure diagram
    --
  4. Then
  5. ACTJFY812 route product structure diagram
    ACTJFY812906559-32-8
Inquiry

Comments (0)